Published mark
Neuphoria Therapeutics Inc.
NASDAQ: NEUP. Canonical company identity and public leadership record.
US
Record source reportedRecord not claimedNo Eval published
- Alpha ID
- alpha:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6
- SEC CIK
- 0001191070
- Record version
- vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 18, 2026
- Newest evidence
- Oct 30, 2025
- Monitoring
- Not yet monitored Details
- Integrity
- Not yet signed Methodology
- CEO
- Spyros PapapetropoulosSince Sep 29, 2025
- Chair
- Not published
- Independent
- 3 / 55 directors published
- Published claims
- 183 distinct sources
- Evidence records
- 50 pinned
- Source conflicts
- 0None open
Built from 3 distinct sources and 5 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.
CorroboratedSource reportedAlpha inferenceNot disclosed
Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works
CEO CHANGED
Spyros Papapetropoulos executive of Neuphoria Therapeutics Inc., effective 2025-09-29.
EffectiveEffective Sep 29, 2025E3
Monitoring
ContinuousWhat the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.
- IdentityunclaimedPublished
- Evidencesource_reportedPublished
- Evaluationnot_evaluatedPublished
- MonitoringNot yet published for this record.Not published
- AuthorityNot yet published for this record.Not published
- FreshnesscurrentPublished
Leadership
Evidence| Role | Person | Since | Status | Claim |
|---|---|---|---|---|
| President, Chief Executive Officer, and Director | Spyros Papapetropoulos | Sep 2025 | current | Source reportedE3 |
| Chief Financial Officer | Tim Cunningham | Sep 2025 | current | Source reportedE4 |
Board of directors
Evidence5 directors published. 3 of 5 with a published determination are independent.
| Director | Status | Since | Committees | Claim |
|---|---|---|---|---|
| Alan Fisher | Independent | 2016 | Audit, chairAudit · Chair; CompensationCompensation | Source reportedE2 |
| David Wilson | Not independent | 2016 | None published | Source reportedE2 |
| Jane Ryan | Independent | 2020 | AuditAudit; Compensation · ChairCompensation, chair | Source reportedE2 |
| Peter Miles Davies | Independent | 2021 | Audit | Source reportedE2 |
| Spyros Papapetropoulos | Not independent | 2023 | None published | Source reportedE2 |
Committees and risk ownership
Evidence| Committee | Chair | Members | Risks assigned |
|---|---|---|---|
| Audit | Alan Fisher | Alan Fisher, Jane Ryan, Peter Miles Davies | Not described in the published record |
| Audit · Chair; Compensation | Not published | Alan Fisher | Not described in the published record |
| Audit; Compensation · Chair | Not published | Jane Ryan | Not described in the published record |
| Compensation | Jane Ryan | Jane Ryan, Alan Fisher | Not described in the published record |
Committee RecordAudit: Chair Alan Fisher; Members Alan Fisher (Chair); Jane Ryan; Peter Miles Davies
Committee AppointmentAlan Fisher: chair, Audit
Committee AppointmentJane Ryan: member, Audit
Committee AppointmentPeter Miles Davies: member, Audit
Committee RecordCompensation: Chair Jane Ryan; Members Jane Ryan (Chair); Alan Fisher
Committee AppointmentJane Ryan: chair, Compensation
Committee AppointmentAlan Fisher: member, Compensation
Control and voting power
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Authority to act
Evidence and agent registryWho can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.
Principal executive officerSpyros Papapetropoulos, President, Chief Executive Officer, and Director, from Sep 29, 2025
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
Financials and market context
EvidenceSecurity ListingNEUP (NASDAQ)
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 18, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.
Governance and policies
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Risk, audit, and cyber
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
AI oversight and accountability
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Legal and regulatory
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Compensation
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Other published claims
EvidencePublished Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.
Legal NameNeuphoria Therapeutics Inc.
Entity StatusPublic listing published
Published FactUS
Not yet in this record
CoverageA gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.
- Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
- FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
- CompensationNot reviewed. Pay design shows how incentives are governed.
- GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
- AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
- LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
- RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
- CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
- Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.
Linked people
Same claims as person records- Spyros PapapetropoulosPresident, Chief Executive Officer, and Directorcompany:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:10, company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:9
- Tim CunninghamChief Financial Officercompany:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:11
- Alan FisherDirectorcompany:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:5
- David WilsonDirectorcompany:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:6
- Jane RyanDirectorcompany:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:7
- Peter Miles DaviesDirectorcompany:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:8
Subject and corrections
Public-role doctrineThis record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.
- Basis
- Published company record built from public sources
- Sources
- 5 evidence records cited. 0 with redistribution rights.
- Never published
- Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
- Record claimed
- No
- Open disputes
- 0
- Identity ownership
- unclaimed
Claiming not yet available
If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.
Evidence
Authority and rights- E1Alpha canonical company public projection. canonical identity. Retrieved Oct 18, 2026. Cited by 4 Claims.
- E2sec proxy. Published Oct 30, 2025. Retrieved Apr 28, 2026. Cited by 5 Claims.
- E3sec filing. Published Sep 29, 2025. Retrieved May 16, 2026. Cited by 1 Claim.
- E4sec filing. Published Sep 29, 2025. Retrieved May 16, 2026. Cited by 1 Claim.
- E5board_seats. board seats. Cited by 7 Claims.
What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 18, 2026- Spyros Papapetropoulos executive of Neuphoria Therapeutics Inc., effective 2025-09-29.
- Tim Cunningham executive of Neuphoria Therapeutics Inc., effective 2025-09-29.
- Spyros Papapetropoulos seat on Neuphoria Therapeutics Inc., effective 2023-01-01.
- Peter Miles Davies seat on Neuphoria Therapeutics Inc., effective 2021-01-01.
- Jane Ryan seat on Neuphoria Therapeutics Inc., effective 2020-01-01.
- Audit; Compensation · Chair committee of Neuphoria Therapeutics Inc., effective 2020-01-01.
- Jane Ryan member of Audit; Compensation · Chair, effective 2020-01-01.
- Alan Fisher seat on Neuphoria Therapeutics Inc., effective 2016-01-01.
- David Wilson seat on Neuphoria Therapeutics Inc., effective 2016-01-01.
- Audit · Chair; Compensation committee of Neuphoria Therapeutics Inc., effective 2016-01-01.
- Alan Fisher member of Audit · Chair; Compensation, effective 2016-01-01.